OKYO Pharma Limited (OKYO) shares climbed 8.00 percent to $2.97 on Wednesday after the company reported positive top-line data from its Phase 2 trial of urcosimod for neuropathic corneal pain, a condition with no FDA-approved treatment. OKYO opened at $3.00 and traded between $2.46 and $3.10 on volume of 1.12 million shares, well above its average of 163,273 on theNasdaq. The stock's 52-week range is $0.81 to $3.11. The randomized, placebo-controlled study showed that patients receiving 0.05 percent urcosimod experienced a mean pain score reduction of 5.5 versus 2.75 for placebo, with 75 percent of patients in the urcosimod group achieving over 80 percent improvement. Statistically significant reductions were observed by Week 4, and the therapy was well-tolerated.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.